Pharmaceutical Technology's Manufacturers' Rankings - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pharmaceutical Technology's Manufacturers' Rankings
Pharmaceutical Technology&s Annual Manufacturers' Rankings provides perspectives on revenues, product positioning, R&D spending, pharmaceutical manufacturing activity, and capital projects of the major drug companies.

Pharmaceutical Technology

Table III: Top 10 products by US sales.*
US sales. Pfizer's Lipitor, which garnered the top spot in global pharmaceutical sales, also ranks first among US products (see Table III). Four other products—Nexium, Advair, Aranesp, and Enbrel—also ranked in the top 10 in both global and US pharmaceutical sales, according to IMS Health.

Despite declining sales resulting from generic competition, Merck & Co.'s Zocor still ranked among the top 10 selling products in the United States, although US sales declined from $4.4 billion in 2005 to $3.1 billion in 2006. TAP Pharmaceutical Products's Prevacid also made the top 10 US product rankings despite a sales decline from $3.8 billion in 2005 to $3.5 billion in 2006.

And three products—Amgen's "Epogen," AstraZeneca's "Seroquel," and Merck & Co.'s "Singulair"—made the top 10 in USrankings but not globally in 2006.

Table IV: Top 10 products by US prescription volume.*
US prescription volumes. Pfizer's Lipitor kept its top position on a volume basis (number of prescriptions dispensed) in the United States with 74 million prescriptions in 2006 (see Table IV). Hydrocodone–acetaminophen (ranked second), escitalopram (ranked ninth), and albuterol (ranked 10th) also kept their rankings in 2006.

Table V: The top 50 by revenue (rankings 1–10)
But other products' positions changed. AstraZeneca's Nexium entered the top 10 in 2006 with 30.4 million prescriptions dispensed in the United States. The antibiotic amoxicillin rose from eighth place in 2005 to fifth place in 2006 with 34.2 million prescriptions. The amount of prescriptions for "Synthroid" fell to 30.9 million last year, a roughly 15% decline since 2005 (see Table IV).

Company rankings

Table V: The top 50 by revenue (rankings 11–20)
Pharmaceutical Executive's "PharmExec 50" (see Table V), an annual ranking of sales revenues and research and development (R&D) investment of the top 50 pharmaceutical companies, reveals key trends. The top seven spots based on global pharmaceutical sales, secured respectively by Pfizer, GSK, Sanofi-Aventis, Novartis, AstraZeneca, J&J, and Merck & Co., remained the same in 2006. BMS, however, fell out of the top 10, moving from ninth in 2005 to eleventh in 2006. Roche moved to eighth in 2006 from twelfth in 2005 (1).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here